Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting

Core Insights - Codexis, Inc. will participate in the RNA Leaders annual meeting on September 4-5, 2024, focusing on enzyme-driven manufacturing of siRNA duplexes [1][2] - The biopharmaceutical industry is advancing RNA manufacturing solutions to enhance production capacities and streamline clinical trials [2] - Codexis' presentations will highlight the cost-effective manufacturing of siRNA duplexes using engineered double-stranded RNA ligases [3] Company Developments - Codexis has launched double-stranded RNA ligase screening and optimization services, which improve siRNA manufacturing by enhancing yield and purity [3] - The ECO Synthesis™ manufacturing platform aims to address scalability and cost limitations in RNAi therapeutics production [6][8] - Recent data presented at TIDES USA 2024 showed over 98% coupling efficiency in enzymatic synthesis of siRNA, comparable to traditional methods [6][7] Industry Context - The demand for RNAi therapeutics is expected to exceed current production capabilities by the end of the decade, with over 450 RNAi therapies in clinical development [5] - Traditional chemical synthesis of RNAi therapeutics faces challenges in quality and economics, highlighting the need for innovative manufacturing solutions [5] - The growth of mRNA vaccines and siRNA candidates in clinical studies underscores the increasing relevance of RNA as a therapeutic modality [5]